Sugi Predict

Sugi Predict / Compounds / SCHEMBL825959

SCHEMBL825959

SCHEMBL825959

CC(C)(C)OC(=O)NC[C@@H](Cc1ccccc1)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 1/20 0.55
▸ SYK P43405 1/20 0.55
▸ CTSS P25774 3/20 0.53
▸ CTSK P43235 2/20 0.53
▸ CTSL P07711 1/20 0.53
▸ CTSB P07858 1/20 0.53
▸ CYP1A2 P05177 1/20 0.53
▸ ACE P12821 1/20 0.51
▸ MEN1 O00255 1/20 0.50
▸ GAA P10253 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ APP P05067 2/20 0.48
▸ IDO1 P14902 1/20 0.48
▸ CPA1 P15085 2/20 0.47
▸ CPA3 P15088 2/20 0.47
▸ FOLH1 Q04609 2/20 0.47
▸ CPB1 P15086 1/20 0.47
▸ CPB2 Q96IY4 1/20 0.47
▸ CA12 O43570 1/20 0.47
▸ CA1 P00915 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1186455 1.00 ATM (0.55) ATMSYKCTSSCTSKCTSL
SCHEMBL3825012 1.00 ATM (0.55) ATMSYKCTSSCTSKCTSL
SCHEMBL13816316 0.89 SYK (0.56) ATMSYKCTSSCTSKCTSL
SCHEMBL990242 0.88 CTSS (0.53) ATMSYKCTSSCTSKCTSL
SCHEMBL2799300 0.88 GAA (0.50) ATMSYKCTSSCTSKCTSL
SCHEMBL3697318 0.88 CTSS (0.56) ATMSYKCTSSCTSKMEN1
SCHEMBL2799041 0.88 GAA (0.50) ATMSYKCTSSCTSKCTSL
SCHEMBL16798329 0.88 CTSS (0.56) ATMSYKCTSSCTSKCTSL
SCHEMBL12101475 0.88 MEN1 (0.47) ATMSYKCTSSCTSKCTSL
SCHEMBL30718545 0.88 CYP17A1 (0.47) ATMSYKCTSSCTSKCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3623372-B1 PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS VALO HEALTH INC (US) 2026-02-04 — — EP disclosed
US-20250346616-A1 ROCK INHIBITORS AND USES THEREOF DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2025-11-13 — — US disclosed
EP-4622996-A1 CONTROL OF NANOCAGE SELF-ASSEMBLY King's College London (GB) 2025-10-01 — — EP disclosed
US-20250206802-A1 MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2025-06-26 — — US disclosed
EP-4532484-A1 ROCK INHIBITORS AND USES THEREOF DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2025-04-09 — — EP disclosed
CN-119173509-A ROCK inhibitors and uses thereof 迪哲(江苏)医药股份有限公司 2024-12-20 — — CN disclosed
US-12018030-B2 Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors VALO HEALTH, INC. (US) 2024-06-25 — — US disclosed
WO-2024110757-A1 CONTROL OF NANOCAGE SELF-ASSEMBLY KING'S COLLEGE LONDON (GB) 2024-05-30 — — WO disclosed
US-20240117006-A1 MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2024-04-11 — — US disclosed
EP-3521301-B1 POLYAMIDE COMPOUND AND USE THEREOF SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) 2024-03-06 — — EP disclosed
WO-2013071049-A1 GRAMICIDIN A MUTANTS THAT FUNCTION AS ANTIBIOTICS WITH IMPROVED SOLUBILITY AND REDUCED TOXICITY TRUSTEES OF BOSTON COLLEGE (US) 2013-05-16 — — WO disclosed
WO-2013071079-A1 LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-05-16 — — WO disclosed
EP-2582715-A2 GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF The Administrators of the Tulane Educational Fund (US) 2013-04-24 — — EP disclosed
US-20130064895-A1 Amphiphilic Peptides and Peptide Particles PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-03-14 — — US disclosed
WO-2013028843-A1 PEPTIDE NANOPARTICLES AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-02-28 — — WO disclosed
WO-2012177986-A2 CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS VYOME BIOSCIENCES (IN) 2012-12-27 — — WO disclosed
WO-2011159917-A2 GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) 2011-12-22 — — WO disclosed
EP-2134175-A1 INHIBITORS OF AKT ACTIVITY Smithkline Beecham Corporation (US) 2009-12-23 — — EP disclosed
EP-1625153-B1 ACYLATED LYSOBACTIN-TYPE NONADEPSIPEPTIDES AICURIS GMBH & CO KG (DE) 2009-08-26 — — EP disclosed
WO-2008121786-A1 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2008-10-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240117006-A1 MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF ITGA2B, ITGB1, ITGA1 ATM 3383/4885SYK 1170/4885CTSS 3462/4885
US-20250346616-A1 ROCK INHIBITORS AND USES THEREOF ROCK1, ROCK2, RHOA ATM 1532/4885SYK 1211/4885CTSS 2671/4885
US-12018030-B2 Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors USP7, UBA7, UBXN1 ATM 2424/4885SYK 2656/4885CTSS 595/4885
US-20250206802-A1 MODIFIED INTEGRIN POLYPEPTIDES, MODIFIED INTEGRIN POLYPEPTIDE DIMERS, AND USES THEREOF ITGA2B, ITGB1, ITGA1 ATM 3383/4885SYK 1170/4885CTSS 3462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.